Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Primary and Secondary Prevention of Postpartum Hemorrhage at the Community Level in Egypt

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Willing and able to give informed consent~* Vaginal delivery~* Agrees to participate in follow-up interview~* Agrees to have pre- and post-hemoglobin taken~* Delivery at woman's home or at the primary health unit (PHU)~Exclusion Criteria:~* Too advanced into active labor to provide consent~* Known allergy to misoprostol and/or other prostaglandin~* Pregnancy complications, such as hypertension, suspected multiple pregnancy, previous caesarean section, suspected still birth, ante-partum hemorrhage, and previous complication in the third trimester

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Secondary prevention (Type: EXPERIMENTAL): Single sublingual dose of 800mcg (4 tablets) misoprostol administered to women with 350-500mL postpartum blood loss as estimated using a blood absorption mat or due to deteriorating postpartum condition of the woman as determined by provider's clinical judgment
- Universal prophylaxis (Type: ACTIVE_COMPARATOR): Single oral prophylactic dose of 600mcg (3 tablets) misoprostol administered to all women within 1 minute of deliver of baby

Based on this trial design, predict the completion outcome and termination type (if applicable).